Literature DB >> 33492696

Quality of recovery scores in deep serratus anterior plane block vs. sham block in ambulatory breast cancer surgery: a randomised controlled trial.

F W Abdallah1, V Patel2, C Madjdpour3, T Cil4, R Brull2.   

Abstract

Deep serratus anterior plane block has been widely adopted as an analgesic adjunct for patients undergoing breast surgery, but robust supporting evidence of efficacy is lacking. We randomly allocated 40 patients undergoing simple or partial mastectomy with sentinel node biopsy to receive either a pre-operative deep serratus anterior plane block (serratus group) or a placebo injection (sham group), in addition to systemic analgesia. The primary outcome measure was the quality of recovery score at discharge, as assessed by the quality of recovery-15 questionnaire at various time-points. Secondary analgesic outcomes included: pain severity; postoperative opioid consumption; opioid-related side-effects; patient satisfaction up to 7 days postoperatively; and persistent postoperative pain up to 3 months after surgery. All patients who were recruited completed the study. There were no differences in the quality of recovery-15 scores between patients in the serratus and control groups, with mean (SD) scores of 96 (14) and 102 (20) for the control and serratus groups, respectively. We were also unable to detect differences in any of the secondary analgesic outcomes examined. The addition of a deep serratus anterior plane block to systemic analgesia does not enhance quality of recovery in patients undergoing ambulatory breast cancer surgery.
© 2021 Association of Anaesthetists.

Entities:  

Keywords:  breast cancer surgery; deep serratus block; postoperative analgesia

Mesh:

Substances:

Year:  2021        PMID: 33492696     DOI: 10.1111/anae.15373

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  6 in total

1.  Impact of Ultrasound-Guided Deep Serratus Anterior Plane Block Combined With Dexmedetomidine as an Adjuvant to Ropivacaine Inpatient Quality of Recovery Scores Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial.

Authors:  Yu Wu; Yuling Kang; Yanli Li; Bohan Fu
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

2.  Assessing Postoperative Benefits of a Nerve Block: Study Design is Critical [Letter].

Authors:  Wen-Xuan Chen; Fu-Shan Xue; Cheng-Wen Li
Journal:  J Pain Res       Date:  2022-01-07       Impact factor: 3.133

Review 3.  Efficacy of Ultrasound-Guided Serratus Anterior Plane Block for Postoperative Analgesia in Patients Undergoing Breast Surgery: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Authors:  Nian-Qiang Hu; Qi-Qi He; Lu Qian; Ji-Hong Zhu
Journal:  Pain Res Manag       Date:  2021-10-25       Impact factor: 3.037

4.  Use of ultrasound guided single shot costotransverse block (intertransverse process) in breast cancer surgery: a prospective, randomized, assessor blinded, controlled clinical trial.

Authors:  Hakan Aygun; Ilker Kiziloglu; Nilgun Kavrut Ozturk; Haydar Ocal; Abdullah Inal; Leyla Kutlucan; Edip Gonullu; Serkan Tulgar
Journal:  BMC Anesthesiol       Date:  2022-04-18       Impact factor: 2.376

5.  The association of Serratus Anterior Plane blocks with postoperative opioid use and analgesia following simple lumpectomy: a retrospective cohort analysis.

Authors:  Brenton Alexander; Soraya Mehdipour; Seung Woo Lee; Engy T Said; Rodney A Gabriel
Journal:  BMC Anesthesiol       Date:  2022-09-15       Impact factor: 2.376

6.  Serratus anterior plane versus paravertebral nerve blocks for postoperative analgesia after non-mastectomy breast surgery: a randomized controlled non-inferiority trial.

Authors:  Rodney A Gabriel; Matthew W Swisher; Jacklynn F Sztain; Brian P Curran; Engy T Said; Wendy B Abramson; Bahareh Khatibi; Brenton S Alexander; John J Finneran; Anne M Wallace; Ava Armani; Sarah Blair; Marek Dobke; Ahmed Suliman; Christopher Reid; Michael C Donohue; Brian M Ilfeld
Journal:  Reg Anesth Pain Med       Date:  2021-06-22       Impact factor: 6.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.